Menu
Currency
GWAS Study

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.

Aslibekyan S, Kabagambe EK, Irvin MR et al.

22228203 PubMed ID
GWAS Study Type
1092 Participants
80 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

AS
Aslibekyan S
KE
Kabagambe EK
IM
Irvin MR
SR
Straka RJ
BI
Borecki IB
TH
Tiwari HK
TM
Tsai MY
HP
Hopkins PN
SJ
Shen J
LC
Lai CQ
OJ
Ordovas JM
AD
Arnett DK
Chapter II

Abstract

Summary of the research findings

Objective: Despite the evidence in support of the anti-inflammatory and triglyceride-lowering effects of fenofibrate, little is known about genetic determinants of the observed heterogeneity in treatment response. This study provides the first genome-wide examination of fenofibrate effects on systemic inflammation.

1,092 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

1092
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.